JP2013509429A5 - - Google Patents

Download PDF

Info

Publication number
JP2013509429A5
JP2013509429A5 JP2012537075A JP2012537075A JP2013509429A5 JP 2013509429 A5 JP2013509429 A5 JP 2013509429A5 JP 2012537075 A JP2012537075 A JP 2012537075A JP 2012537075 A JP2012537075 A JP 2012537075A JP 2013509429 A5 JP2013509429 A5 JP 2013509429A5
Authority
JP
Japan
Prior art keywords
compound
following structure
following
pharmaceutically acceptable
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012537075A
Other languages
English (en)
Other versions
JP2013509429A (ja
JP5529282B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/054546 external-priority patent/WO2011059763A2/en
Publication of JP2013509429A publication Critical patent/JP2013509429A/ja
Publication of JP2013509429A5 publication Critical patent/JP2013509429A5/ja
Application granted granted Critical
Publication of JP5529282B2 publication Critical patent/JP5529282B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (20)

  1. 遊離塩基型を含む以下の化合物:
    Figure 2013509429
    Figure 2013509429
    Figure 2013509429
    Figure 2013509429
    Figure 2013509429
    Figure 2013509429
    からなる群より選択される化合物、又はその化合物の製薬上許容される塩及びその立体異性体型。
  2. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  3. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  4. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  5. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  6. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  7. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  8. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  9. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  10. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  11. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  12. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  13. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  14. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  15. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  16. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  17. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  18. 以下の構造:
    Figure 2013509429
    を有する請求項1に記載の化合物。
  19. 請求項1に記載の化合物及び少なくとも一つの製薬上許容される賦形剤を含む医薬組成物であって、さらに、少なくとも一つの別の治療薬として腫瘍壊死因子関連アポトーシス誘導リガンド(TRAIL)を含む医薬組成物。
  20. 細胞を有効量の請求項1に記載の化合物と接触させることで、細胞増殖を低下または細胞死を誘発するための医薬の製造における請求項1に記載の化合物の使用。
JP2012537075A 2009-10-28 2010-10-28 二量体Smac模倣薬 Expired - Fee Related JP5529282B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25578809P 2009-10-28 2009-10-28
US61/255,788 2009-10-28
PCT/US2010/054546 WO2011059763A2 (en) 2009-10-28 2010-10-28 Dimeric smac mimetics

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014084316A Division JP2014167006A (ja) 2009-10-28 2014-04-16 二量体Smac模倣薬

Publications (3)

Publication Number Publication Date
JP2013509429A JP2013509429A (ja) 2013-03-14
JP2013509429A5 true JP2013509429A5 (ja) 2013-12-05
JP5529282B2 JP5529282B2 (ja) 2014-06-25

Family

ID=43992315

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012537075A Expired - Fee Related JP5529282B2 (ja) 2009-10-28 2010-10-28 二量体Smac模倣薬
JP2014084316A Pending JP2014167006A (ja) 2009-10-28 2014-04-16 二量体Smac模倣薬

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014084316A Pending JP2014167006A (ja) 2009-10-28 2014-04-16 二量体Smac模倣薬

Country Status (6)

Country Link
US (2) US8551955B2 (ja)
EP (2) EP2493879B1 (ja)
JP (2) JP5529282B2 (ja)
CN (1) CN102958928B (ja)
CA (1) CA2789879A1 (ja)
WO (1) WO2011059763A2 (ja)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9453048B2 (en) * 2012-08-09 2016-09-27 Bristol-Myers Squibb Company IAP antagonists
PE20150674A1 (es) * 2012-08-15 2015-05-06 Hoffmann La Roche Azaheterociclos como inhibidores de bir2 y/o bir3
EP2903998B1 (en) * 2012-10-02 2017-03-15 Bristol-Myers Squibb Company Iap antagonists
WO2014056867A1 (en) * 2012-10-11 2014-04-17 F. Hoffmann-La Roche Ag Azaindolines
PE20150965A1 (es) 2012-10-11 2015-06-20 Hoffmann La Roche Azaindolinas
CA2887497A1 (en) * 2012-12-11 2014-06-19 Steven Gregory Mischke Dimeric compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3019517A1 (en) * 2013-07-12 2016-05-18 Bristol-Myers Squibb Company Iap antagonists
MY186570A (en) 2014-05-13 2021-07-27 Novartis Ag Compounds and compositions for inducing chondrogenesis
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
AU2016209349B2 (en) 2015-01-20 2020-05-07 Arvinas, Inc. Compounds and methods for the targeted degradation of the Androgen Receptor
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
MX2018000471A (es) * 2015-07-13 2018-04-10 Arvinas Inc Moduladores de proteolisis basados en alanina y metodos de uso asociados.
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
CA3042260C (en) 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
EP3689868B1 (en) 2016-12-01 2023-09-27 Arvinas Operations, Inc. Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
EP3559006A4 (en) 2016-12-23 2021-03-03 Arvinas Operations, Inc. COMPOUNDS AND METHODS FOR TARGETED DEGRADATION OF FETAL LIVER KINASE POLYPEPTIDES
RU2019121527A (ru) 2016-12-23 2021-01-15 Эрвинэс Оперейшнс, Инк. Химерные молекулы, нацеливающиеся на протеолиз egfr, и связанные с ними способы применения
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
KR20230140606A (ko) 2017-01-26 2023-10-06 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 단백질 분해 조절제 및 관련 사용 방법
US11261175B2 (en) 2017-09-22 2022-03-01 Seoul National University R&Db Foundation Fluorene derivative or pharmaceutically acceptable salt thereof, preparation method therefor, and pharmaceutical composition comprising same as effective ingredient for preventing or treating HCV-related disease
EP3710443A1 (en) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
WO2020110056A1 (en) 2018-11-30 2020-06-04 Glaxosmithkline Intellectual Property Development Limited Compounds useful in hiv therapy
EP3911316A1 (en) 2019-01-17 2021-11-24 Debiopharm International SA Combination product for the treatment of cancer
KR20220012844A (ko) 2019-04-05 2022-02-04 헤파진 테라퓨틱스 (에이치케이) 리미티드 아포토시스 단백질 억제제의 2가 길항제
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
CA3151770A1 (en) 2019-09-25 2021-04-01 Silvano BRIENZA Dosing regimens for treatment of patients with locally advanced squamous cell carcinoma
BR112023018321A2 (pt) 2021-03-15 2024-01-02 Maze Therapeutics Inc Inibidores de glicogênio sintase 1 (gys1) e métodos de uso dos mesmos
EP4190452A1 (de) 2021-12-01 2023-06-07 Eppendorf SE Abstandshalter zum halten von übereinandergestapelten pipettenspitzenträgern auf abstand voneinander
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
GB9213215D0 (en) * 1992-06-20 1992-08-05 Wellcome Found Peptides
US5387584A (en) 1993-04-07 1995-02-07 Pfizer Inc. Bicyclic ansamycins
US5932566A (en) 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US6790785B1 (en) 2000-09-15 2004-09-14 The Board Of Trustees Of The University Of Illinois Metal-assisted chemical etch porous silicon formation method
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
US7138402B2 (en) 2003-09-18 2006-11-21 Conforma Therapeutics Corporation Pyrrolopyrimidines and related analogs as HSP90-inhibitors
EP1723122B1 (en) 2004-03-01 2014-11-19 Board of Regents, The University of Texas System Dimeric small molecule potentiators of apoptosis
AU2005228950B2 (en) 2004-03-23 2012-02-02 Genentech, Inc. Azabicyclo-octane inhibitors of IAP
KR20080083220A (ko) 2004-04-07 2008-09-16 노파르티스 아게 Iap 억제제
PT1778718E (pt) 2004-07-02 2014-12-03 Genentech Inc Inibidores de iap
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
DE602005022936D1 (de) 2004-12-20 2010-09-23 Genentech Inc Pyrrolidine als inhibitoren von iap
ES2456671T3 (es) 2005-02-25 2014-04-23 Tetralogic Pharmaceuticals Corporation Inhibidores diméricos de IAP
CA2607940C (en) * 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
AU2006279929A1 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
EP1951698A4 (en) 2005-10-25 2010-04-28 Aegera Therapeutics Inc BINDING COMPOUNDS TO THE IAP BIR DOMAIN
TWI543988B (zh) * 2006-03-16 2016-08-01 科學製藥股份有限公司 結合於細胞凋亡抑制蛋白(iap)之桿狀病毒iap重複序列(bir)區域之化合物
CA2646186A1 (en) 2006-03-21 2007-11-29 Joyant Pharmaceuticals, Inc. Small molecule apoptosis promoters
NZ572836A (en) 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
NZ580313A (en) * 2007-04-12 2011-11-25 Joyant Pharmaceuticals Inc Smac mimetic dimers and trimers useful as anti-cancer agents
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors

Similar Documents

Publication Publication Date Title
JP2013509429A5 (ja)
JP2013518107A5 (ja)
JP2013525444A5 (ja)
JP2011102304A5 (ja)
JP2013014622A5 (ja)
JP2012255026A5 (ja)
JP2014507446A5 (ja)
JP2014521735A5 (ja)
JP2015536964A5 (ja)
JP2013507439A5 (ja)
JP2017524735A5 (ja)
JP2013032389A5 (ja)
JP2012532874A5 (ja)
JP2016515561A5 (ja)
JP2012193216A5 (ja)
JP2012512907A5 (ja)
JP2015516419A5 (ja)
JP2011527299A5 (ja)
JP2012502037A5 (ja)
JP2009545527A5 (ja)
JP2013522326A5 (ja)
JP2014503593A5 (ja)
JP2013542261A5 (ja)
ECSP12011703A (es) Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos
JP2012519182A5 (ja)